Menu
No results found.
Weekly Share Price & Valuation Overview
Illumina, Inc.
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 15.85B
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 16.83B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 4.28B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 2.92B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD 692.00M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 27.03
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 7.90
- Shares Outstanding
- 158.30M
- Float Shares
- 149.35M
- Implied Shares Outstanding
- 159.12M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
18.79%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
16.15%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
68.16%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
29.34%
- ROA Return on assets: net income ÷ total assets.
-
4.25%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
68.06%
- Revenue Growth Year-over-year revenue growth.
-
-4.80%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.28
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.15
- Total Cash Cash and equivalents.
- USD 1.16B
- Total Debt Short + long-term interest-bearing debt.
- USD 2.60B
- Net Debt Total debt − cash (negative = net cash).
- USD 1.44B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 3.75
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD 1.15B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 111.38M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
26.94%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
2.60%
- Cash Conversion (OpCF/EBITDA)
- 1.67
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.